TY - JOUR
T1 - A new transseptal solution for enabling left atrial access of large delivery sheaths
AU - Inohara, Taku
AU - Gilhofer, Thomas
AU - Al-Dujaili, Saja
AU - Leung, Linus
AU - Yeung, Darwin
AU - Tsang, Michael
AU - Saw, Jacqueline
N1 - Funding Information:
: Dr. Jacqueline Saw has received unrestricted research grant supports (from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, National Institutes of Health, AstraZeneca, Abbott Vascular, St. Jude Medical, Boston Scientific, and Servier), salary support (Michael Smith Foundation for Health Research), speaker honoraria (AstraZeneca, Abbott Vascular, Boston Scientific, Bayer), consultancy and advisory board honoraria (AstraZeneca, Boston Scientific, Abbott Vascular, Gore, Abiomed, Baylis, and FEops), and proctorship honoraria (Abbott Vascular and Boston Scientific). Other authors: No disclosures. Disclosures
Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2021/3
Y1 - 2021/3
N2 - Background: Transseptal access for large sheaths may be encumbered by tissue resistance against the sheath–dilator stepped interface. The ExpanSure Large Access Transseptal Dilator (Baylis Medical) is designed as a single introducer and dilation device with a smooth sheath–dilator transition to support transseptal puncture. It may facilitate ease and efficiency of interatrial crossing. Methods: This study experimentally evaluated the crossing force of ExpanSure relative to a conventional 8.5 F Swartz SL1 transseptal sheath and dilator in a benchtop septum model. Its ability to reduce the subsequent crossing force of a 14 F WATCHMAN delivery sheath was also tested. The clinical use of ExpanSure, including procedure time, was then validated in a series of left atrial appendage closure (LAAC) procedures. Results: In a benchtop septum model (N = 12), less peak force (1.90 ± 0.08 N vs. 2.36 ± 0.09 N; p <.001) and overall work (17.3 ± 1.2 mJ vs. 28.0 ± 1.9 mJ; p <.001) were required to advance ExpanSure relative to a conventional SL1 transseptal sheath and dilator system. Peak force (2.34 ± 0.24 N vs. 2.65 ± 0.21 N; p <.003) and overall work (28.5 ± 3.9 mJ vs. 35.4 ± 2.1 mJ; p <.001) to advance a WATCHMAN sheath were also significantly lower after using ExpanSure than after using a conventional transseptal system. In 19 LAAC procedures, ExpanSure crossed the septum smoothly and integrated readily, which enabled efficient procedure completion (mean total procedure time 37.6 ± 13.5 min), with 100% success and no procedure-related complications. Conclusion: Experimental force measurements, combined with early clinical experience using ExpanSure, suggest that the tapered design with smooth transition without dilator–sheath step-up and the larger diameter, both facilitated ease and efficiency of interatrial crossing.
AB - Background: Transseptal access for large sheaths may be encumbered by tissue resistance against the sheath–dilator stepped interface. The ExpanSure Large Access Transseptal Dilator (Baylis Medical) is designed as a single introducer and dilation device with a smooth sheath–dilator transition to support transseptal puncture. It may facilitate ease and efficiency of interatrial crossing. Methods: This study experimentally evaluated the crossing force of ExpanSure relative to a conventional 8.5 F Swartz SL1 transseptal sheath and dilator in a benchtop septum model. Its ability to reduce the subsequent crossing force of a 14 F WATCHMAN delivery sheath was also tested. The clinical use of ExpanSure, including procedure time, was then validated in a series of left atrial appendage closure (LAAC) procedures. Results: In a benchtop septum model (N = 12), less peak force (1.90 ± 0.08 N vs. 2.36 ± 0.09 N; p <.001) and overall work (17.3 ± 1.2 mJ vs. 28.0 ± 1.9 mJ; p <.001) were required to advance ExpanSure relative to a conventional SL1 transseptal sheath and dilator system. Peak force (2.34 ± 0.24 N vs. 2.65 ± 0.21 N; p <.003) and overall work (28.5 ± 3.9 mJ vs. 35.4 ± 2.1 mJ; p <.001) to advance a WATCHMAN sheath were also significantly lower after using ExpanSure than after using a conventional transseptal system. In 19 LAAC procedures, ExpanSure crossed the septum smoothly and integrated readily, which enabled efficient procedure completion (mean total procedure time 37.6 ± 13.5 min), with 100% success and no procedure-related complications. Conclusion: Experimental force measurements, combined with early clinical experience using ExpanSure, suggest that the tapered design with smooth transition without dilator–sheath step-up and the larger diameter, both facilitated ease and efficiency of interatrial crossing.
KW - ExpanSure
KW - atrial fibrillation
KW - left atrial appendage closure
KW - transseptal puncture
UR - http://www.scopus.com/inward/record.url?scp=85100072600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100072600&partnerID=8YFLogxK
U2 - 10.1111/jce.14903
DO - 10.1111/jce.14903
M3 - Article
C2 - 33476450
AN - SCOPUS:85100072600
SN - 1045-3873
VL - 32
SP - 729
EP - 734
JO - Journal of Cardiovascular Electrophysiology
JF - Journal of Cardiovascular Electrophysiology
IS - 3
ER -